<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04162535</url>
  </required_header>
  <id_info>
    <org_study_id>418/14.11.2018</org_study_id>
    <nct_id>NCT04162535</nct_id>
  </id_info>
  <brief_title>Elucidation of the Mechanisms and Effects of Certain Anesthetic Interventions on Digestive Cancer Patients Subjected to Surgery</brief_title>
  <official_title>Contributions to the Elucidation of the Mechanisms and Effects by Which Certain Perianesthetic Interventions Modify Long-term Evolution of Patients With Digestive Cancers Subjected to Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Iuliu Hatieganu University of Medicine and Pharmacy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institutul Regional de Gastroenterologie &amp; Hepatologie Prof. dr. Octavian Fodor</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Prof. Dr. I. Chiricuta Institute of Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Iuliu Hatieganu University of Medicine and Pharmacy</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Digestive cancers (liver, colonic, pancreatic) have a high incidence and high mortality,
      their population prevalence is also increasing. Given that the anesthesia techniques and the
      agents used act directly and indirectly on the immune system during the perioperative period,
      influencing both the treatment and the prognosis of patients with colorectal cancer who
      undergo elective interventions, a series of perianesthetic interventions have been proposed
      in order to reduce morbidity-mortality perioperative.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 26, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the antiproliferative and apoptotic effects of anesthetic agents</measure>
    <time_frame>up to 4 years</time_frame>
    <description>The investigators aim to correlate the anticancer effects of two anesthetic techniques with tumor markers (p53;p38) and cell proteins involved in proliferation or apoptosis (IGFR;Bcl-2;Bcl-6).
The investigators will report if the anesthetic agent used in cancer surgery influences the serologic values of these markers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of patients serum on cell culture</measure>
    <time_frame>up to 1 week</time_frame>
    <description>The investigators will investigate the serum of the patients who received different types of anesthesia (elective colorectal cancer surgery) by incubating it with colon cell lines (HCT116). The investigators will concentrate on cell proliferation assay.
The investigators aim to discover how the growth of HCT116 will be influenced by patients' serum in terms of rate of proliferation. The measurements which will be used are Inhibitory Concentration (IC50) measured at 0 , 24 and 48 hours after incubation.
The concentrations will be measured in mcg/ml.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lidocaine concentration</measure>
    <time_frame>up to 4 years</time_frame>
    <description>The investigators aim to determine de plasmatic concentration of lidocaine in the patients serum , which have received lidocaine perioperatively.
The investigators will do a Mass-Spec analysis of lidocaine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival Comparison</measure>
    <time_frame>up to 5 years</time_frame>
    <description>The investigators will do a follow up for the patients in all the 3 groups. The investigators want to investigate the survival ratio for the patients that had a elective colorectal cancer surgery.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Sevoflurane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a general volatile anesthesia with Sevoflurane as anesthetic agent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Total intravenous anesthesia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a general anesthesia with Propofol as anesthetic agent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Total intravenous anesthesia and Lidocaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a general anesthesia with Propofol as anesthetic agent and will also receive a fully lidocaine infusion according to the lidocaine protocol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>10 presumed healthy volunteers that have donated 10 ml of venous blood for serum comparison</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine 1% Injectable Solution</intervention_name>
    <description>Lidocaine 1% Injectable Solution Intervention Protocol for the TIVA and Lidocaine Arm
Induction: 1.5 mg / kg i.v. bolus before induction (at the vein catch).
Maintaining anesthesia: continuous infusion with Lidocaine 2 mg / kg / h, up to a maximum of 200 mg / h during maintenance (after IOT until waking)
Infusion with 1% Lidocaine will be reduced to 1.0- 1.5 mg / kg / hour, max 100 mg / hour, for the first 48 hours postop</description>
    <arm_group_label>Total intravenous anesthesia and Lidocaine</arm_group_label>
    <other_name>Antiarrythmic drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood extraction</intervention_name>
    <description>The patients will donate after consent 10 ml of blood prior and after surgery for further study</description>
    <arm_group_label>Sevoflurane</arm_group_label>
    <arm_group_label>Total intravenous anesthesia</arm_group_label>
    <arm_group_label>Total intravenous anesthesia and Lidocaine</arm_group_label>
    <other_name>Biologic Human Blood</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>Patients will receive a general volatile anesthesia with Sevoflurane as anesthetic agent</description>
    <arm_group_label>Sevoflurane</arm_group_label>
    <other_name>Volatile Anesthetic Drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Patients will receive a general anesthesia with Propofol as anesthetic agent</description>
    <arm_group_label>Total intravenous anesthesia</arm_group_label>
    <other_name>Intravenous Anesthetic Drug</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 to 80 years old patients admitted for elective colorectal surgery

        Exclusion Criteria:

          -  Pre-existing chronic pain

          -  Chronic medication that may interfere with pain: antiepileptics, NSAIDs,
             corticosteroids

          -  Contraindications to any of the medications in the study

          -  Significant psychiatric disorders (Axis I disorder) (major depressive disorders,
             bipolar disorders, schizophrenia, etc.)

          -  Hepatic (ALT and / or AST&gt; 2 normal wave) or renal (serum creatinine&gt; 2 mg / dl)

          -  Convulsive conditions that require medication in the last 2 years

          -  Planned regional analgesia and / or anesthesia (spinal or epidural)

          -  Corticosteroid-dependent asthma

          -  Autoimmune disorders

          -  Antiarrhythmic drugs (verapamil, propafenone, amiodarone) that may interfere with the
             antiarrhythmic action of lidocaine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ionescu Daniela, MD PHD DEEA</last_name>
    <role>Study Director</role>
    <affiliation>UMF Iuliu Hatieganu Cluj-Napoca</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexandru Alexa, MD</last_name>
    <phone>+40752691911</phone>
    <email>alexandru_reziati@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ionescu Daniela, MD PHD</last_name>
    <phone>0744771209</phone>
    <email>dionescuati@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institutu Regional de Gastroenterologie si Hepatologi Prof. Dr. O. Fodor</name>
      <address>
        <city>Cluj-Napoca</city>
        <state>Cluj</state>
        <zip>400469</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandru Alexa</last_name>
      <phone>+40752691911</phone>
      <email>alexandru_reziati@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Romania</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 13, 2019</study_first_submitted>
  <study_first_submitted_qc>November 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2019</study_first_posted>
  <last_update_submitted>November 10, 2019</last_update_submitted>
  <last_update_submitted_qc>November 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Iuliu Hatieganu University of Medicine and Pharmacy</investigator_affiliation>
    <investigator_full_name>Alexandru Alexa</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Anesthesia</keyword>
  <keyword>Propofol</keyword>
  <keyword>Sevoflurane</keyword>
  <keyword>Lidocaine</keyword>
  <keyword>Cell Culture</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Anesthetics, Intravenous</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

